Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT3001 in Advanced Solid Tumors
NCT06598007Phase 2Recruiting
- Sponsor
- Crossignal Therapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ct3001 in solid tumor, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Crossignal Therapeutics. Started Sep 2024; status: recruiting.
02
Drugs
ct3001
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06598007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598007.